



Hong Song, MD, PhD

Assistant Professor of Radiology (Nuclear Medicine)

Radiology - Rad/Nuclear Medicine

CLINICAL OFFICE (PRIMARY)

- **Diagnostic Radiology**

300 Pasteur Dr Rm S092

MC 5105

Stanford, CA 94305

Tel (650) 723-4527 **Fax** (650) 723-1909

Bio

BIO

Hong Song received his MD from Tulane University School of Medicine and a Ph.D. in Chemical Engineering from Tulane University. He performed research in targeted radionuclide therapy as a postdoctoral fellow at the Johns Hopkins University. Following medical school, he joined Dual pathway Nuclear Medicine and Diagnostic Radiology residency at Stanford. His current research interests include PSMA PET in biochemically recurrent prostate cancer and DOTATATE PET in PRRT for neuroendocrine tumors.

CLINICAL FOCUS

- Nuclear Radiology

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Radiology - Rad/Nuclear Medicine
- Member, Stanford Cancer Institute

PROFESSIONAL EDUCATION

- Board Certification: Diagnostic Radiology, American Board of Radiology (2023)
- Board Certification: Nuclear Medicine, American Board of Nuclear Medicine (2022)
- Residency: Stanford University Radiology Residency (2022) CA
- Internship: Tulane University Internal Medicine Residency (2017) LA
- Medical Education: Tulane University School of Medicine Registrar (2016) LA

Research & Scholarship

CLINICAL TRIALS

- ⁶⁴Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE), Not Recruiting

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Elisabeth Heidi Guenther

Publications

PUBLICATIONS

- **Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy.** *Journal for immunotherapy of cancer*
Handke, A., Kesch, C., Fendler, W. P., Telli, T., Liu, Y., Hakansson, A., Davicioni, E., Hughes, J., Song, H., Lueckerath, K., Herrmann, K., Hadaschik, B., Seifert, et al
2023; 11 (10)
- **Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET.** *European journal of nuclear medicine and molecular imaging*
Duan, H., Davidzon, G. A., Moradi, F., Liang, T., Song, H., Iagaru, A.
2023
- **Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression free survival in patients with prostate cancer**
Song, H., Sjostrand, K., Duan, H., Ferri, V., Aparici, C., Davidzon, G., Franc, B., Moradi, F., Anand, A., Iagaru, A.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting.** *European journal of nuclear medicine and molecular imaging*
Song, H., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., Moradi, F., Nguyen, J., Shah, J., Iagaru, A.
2023
- **64Cu-DOTATATE Uptake in a Pulmonary Hamartoma.** *Clinical nuclear medicine*
Song, H., Guja, K. E., Yang, E. J., Guo, H. H.
2023; 48 (1): 58-60
- **Biodistribution of a Mitochondrial Metabolic Tracer, [18F]F-AraG, in Healthy Volunteers.** *Molecular imaging*
Levi, J., Duan, H., Yaghoubi, S., Packiasamy, J., Huynh, L., Lam, T., Shaikh, F., Behera, D., Song, H., Blecha, J., Jivan, S., Seo, Y., VanBrocklin, et al
2022; 2022: 3667417
- **Results of First Interim Analysis of 68Ga-NeoB and 68Ga-PSMA R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer**
Duan, H., Song, H., Davidzon, G., Moradi, F., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2022
- **PSMA theragnostics for metastatic castration resistant prostate cancer.** *Translational oncology*
Song, H., Guja, K. E., Iagaru, A.
2022; 22: 101438
- **68Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Moradi, F., Duan, H., Song, H., Davidzon, G. A., Chung, B. I., Thong, A. E., Loening, A. M., Ghanouni, P., Sonn, G., Iagaru, A.
2022
- **The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors.** *Frontiers in immunology*
Levi, J., Song, H.
2022; 13: 1113924
- **18F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Song, H., Iagaru, A., Rowe, S. P.

2021

- **PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING**

Baratto, L., Song, H., Duan, H., Moradi, F., Davidzon, G., Iagaru, A.
LIPPINCOTT WILLIAMS & WILKINS.2021: E1178

- **PROSPECTIVE EVALUATION OF F-18-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF F-18-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES**

Song, H., Nguyen, J., Moradi, F., Aparici, C., Franc, B., Davidzon, G., Iagaru, A.
LIPPINCOTT WILLIAMS & WILKINS.2021: E1177-E1178

- **PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*

Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., Hancock, S., Shah, S. A., Srinivas, S., Swift, P., Moradi, F., Davidzon, G. A., Iagaru, et al
2021

- **18F-FDG PET/CT for Evaluation of Post-Transplant Lymphoproliferative Disorder (PTLD).** *Seminars in nuclear medicine*

Song, H., Guja, K. E., Iagaru, A.
2021

- **Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management** *CLINICAL NUCLEAR MEDICINE*

Song, H., Mosci, C., Akatsu, H., Basina, M., Dosiou, C., Iagaru, A.
2018; 43 (10): 705–9

- **Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Xofigo (R) in mCRPC Patients**

Song, H., Yohannan, T., Srinivas, S., Vasanawala, S., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2018